[A case of meningoencephalitis associated with pembrolizumab treated for squamous cell lung cancer].
Rinsho Shinkeigaku
; 59(2): 105-108, 2019 Feb 23.
Article
in Ja
| MEDLINE
| ID: mdl-30700688
ABSTRACT
A 61-year-old man with squamous cell lung cancer was admitted to our hospital because of consciousness disturbance after treated with pembrolizumab. Cerebrospinal fluid examination revealed increased protein level (209.2â
mg/dl) and lymphocytic pleocytosis(79/µl). He was diagnosed as a meningoencephalitis probably caused by an immune-related adverse event (irAE) of immune checkpoint inhibitors (ICIs), and was successfully treated with 1,000â
mg methylprednisolone intravenously for 3 days twice and the consequent oral 1â
mg/kg prednisolone. As ICIs, which activate the immune systems, are becoming important choices of the treatments against malignancies, we should keep the possibility of irAE in mind and, when needed, start the treatment as soon as possible.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Methylprednisolone
/
Carcinoma, Squamous Cell
/
Antibodies, Monoclonal, Humanized
/
Antineoplastic Agents, Immunological
/
Lung Neoplasms
/
Meningoencephalitis
Type of study:
Risk_factors_studies
Limits:
Humans
/
Male
/
Middle aged
Language:
Ja
Journal:
Rinsho Shinkeigaku
Year:
2019
Document type:
Article